About: Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis
Creator	Alizadeh-Navaei, Reza Heydari, Keyvan Shamshirian, Amir Shamshirian, Danial Ghasemian, Roya Hessami, Amirhossein Aboufazeli, Elham Baradaran, Hananeh Ebrahimzadeh, Mohammad Eftekhari, Aida Karimifar, Keyvan
source	MedRxiv
abstract	Background: Coronavirus Disease 2019 (COVID-19) has become a major global issue with rising the number of infected individuals and mortality in recent months. Among all therapeutic approaches, arguments have raised about hydroxychloroquine efficacy in treatment of COVID-19. We aimed to overcome the controversies regarding effectiveness of hydroxychloroquine in treatment of COVID-19, using a systematic review and meta-analysis. Methods: A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar and medRxiv pre-print database using all available MeSH terms for COVID-19 and hydroxychloroquine. Two authors selected and assessed the quality of studies independently using related checklists. Data have been extracted from included studies and analyzed using CMA v. 2.2.064. heterogeneity was also assessed using I-squared test. Results: Seven studies including four clinical trials and three observational studies have entered into the study. The results of meta-analysis of clinical trials showed that there were no significant differences between patients who received the standard treatment with HCQ regimen and the patients that received the standard treatment without HCQ (RR: 1.44, 95% CI, 0.80-2.59). CT-Scan findings improved in 59% (95% CI 0.15-0.92) and nasopharyngeal culture following RT-PCR resulted negative in 76% (95% CI 0.56-0.89) of patients received hydroxychloroquine. Meta-analysis of observational studies showed 75% (95% CI, 0.54-0.88) of patients were discharged from the hospital, 34% (95% CI, 0.07-0.14) admitted to intensive care unit and 1.5% (95% CI, 0.03-0.83) have expired. Conclusion: This study indicated no clinical benefits regarding HCQ for treatment of COVID-19 patients. However, further large clinical trials should be taken into account in order to achieve more reliable findings.
has issue date	2020-04-20(xsd:dateTime)
bibo:doi	10.1101/2020.04.14.20065276
has license	medrxiv
sha1sum (hex)	d831dbf38025a44e0436fd11c52af4db9eb7c5b0
schema:url	https://doi.org/10.1101/2020.04.14.20065276
resource representing a document's title	Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis
resource representing a document's body	covid:d831dbf38025a44e0436fd11c52af4db9eb7c5b0#body_text
is schema:about of	named entity 'raised' named entity 'arguments' named entity 'COVID-19' named entity 'therapeutic approaches' named entity 'Coronavirus Disease 2019' named entity 'COVID' named entity 'COVID' named entity 'COVID' named entity 'Hydroxychloroquine' named entity 'COVID' named entity 'PubMed' named entity 'COVID' named entity 'systematic review' named entity 'COVID-19' named entity 'case reports' named entity 'HCQ' named entity 'SARS-CoV-2' named entity 'meta-analysis' named entity 'preprint' named entity 'MeSH' named entity 'preprint' named entity 'WHO' named entity 'Detroit' named entity 'adverse effects' named entity 'control group' named entity 'preprint' named entity 'HCQ' named entity '95% CI' named entity 'meta-analysis' named entity 'peer-reviewed' named entity 'Clinical Trials' named entity 'preprint' named entity 'HCQ' named entity 'Coronavirus Disease 2019' named entity 'clinical trials' named entity 'HCQ' named entity 'contaminated environments' named entity 'RT-PCR' named entity '95% CI' named entity 'Scopus' named entity 'COVID' named entity 'gray literature' named entity '95% CI' named entity 'HCQ' named entity 'Randomised Controlled Trial' named entity 'chloroquine' named entity '0.80' named entity 'quarantine' named entity 'Hydroxychloroquine' named entity 'infection' named entity 'clinical trials registry' named entity 'significant difference' named entity 'medRxiv' named entity 'publication bias' named entity '95% CI' named entity 'anti-inflammatory agent' named entity 'azithromycin' named entity 'HCQ' named entity 'HCQ' named entity 'Cochrane Library' named entity 'Chikungunya Virus' named entity 'randomized clinical trials' named entity 'HCQ' named entity 'HCQ' named entity 'preprint' named entity 'coronavirus' named entity 'effect size' named entity 'Michigan' named entity 'CID' named entity 'COVID' named entity 'peer-reviewed' named entity 'Data extraction' named entity 'Statistical analysis' named entity 'COVID-19' named entity 'letter to the editor'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software